Breast Cancer

Adding anti-obesity medication for survivors who do not respond early to lifestyle changes helps 42% achieve clinically meaningful weight loss.

AMH and INHB testing can identify premenopausal patients with HR+/HER2- breast cancer who may safely avoid chemotherapy, sparing unnecessary toxicity.

Theresa Lynne Harrington Stukus, ANPBC NP, discusses patient compliance, side effect management, and screening anxiety in breast cancer care.

A Neurology study reveals breast cancer survivors have a high ischemic stroke risk within one year of diagnosis, linked to specific treatment regimens.

FDA approves gedatolisib with fulvestrant for adults with HR+/HER2- metastatic breast cancer following endocrine therapy progression.

Experts explore the clinical promise, nursing implications, and access barriers of GLP-1s in cancer care.

Dr. Sonja J. Hughes discusses managing GI toxicities and the need for research regarding GLP-1 use among breast cancer patients and survivors.

FDA approves sacituzumab govitecan-hziy as monotherapy and with pembrolizumab for first-line treatment of advanced triple-negative breast cancer.

The FDA approved palbociclib (Ibrance) for maintenance in HR+/HER2+ metastatic breast cancer after induction therapy, based on the PATINA trial.

Dr. Loren Rourke discusses how GLP-1s may impact breast cancer risk by reducing adipose tissue-derived estrogen and chronic metabolic inflammation.

TROPION-Breast02 data show datopotamab deruxtecan extends stability and delays the need for new treatment lines in first-line metastatic TNBC.

Camizestrant switch at ESR1 mutation detection improves PFS, patient-reported outcomes, and delays chemotherapy in advanced breast cancer.

ASCO 2026 data show GLP-1 RAs reduce HR+/HER2- breast cancer risk and improve overall survival in non-diabetic women with a BMI of 25-35 kg/m².

New ASCENT-04 data shows sacituzumab govitecan plus pembrolizumab improves PFS in first-line PD-L1+ TNBC regardless of Trop-2, BRCA, or HER2 status.

Dr. Emily Podany explains how oncology nurses can screen for food insecurity and provide evidence-based solutions to improve patient outcomes.

Dr. Paolo Tarantino highlights the need for drug-specific prophylaxis to manage toxicities like ILD and neutropenia in patients receiving ADCs.

Final KEYNOTE-522 analysis shows 85.1% 7-year OS in early TNBC. Dr. Javier Cortes details nursing management of immune-related side effects.

Studies to be presented at the 2026 ASCO Annual Meeting examine GLP-1 receptor agonists in relation to cancer progression, survival, and immune-related adverse events.

Study findings suggest biologic aging and neighborhood deprivation may shape cognitive benefits from exercise after breast cancer.

The FDA approved T-DXd for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, showing improved pCR and IDFS rates.

Experts warn of "molecular anxiety" and financial toxicity as ctDNA testing enters early-stage breast cancer surveillance.

Learn about the FDA approval of vepdegestrant (Veppanu), the first PROTAC for ESR1-mutated breast cancer, including nursing priorities and side effects.

FDA approved Veppanu for ER+, HER2- ESR1-mutated breast cancer after endocrine therapy, improving PFS to 5 months vs 2.1 and reducing progression risk by 43%.

Paget disease of the breast: key signs, diagnosis, and treatment strategies oncology nurses should know to support early detection and patient care.